Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Krystal Biotech Inc (KRYS), Prevail Therapeutics Inc (PRVL) and Intec Pharma Ltd (NTEC).
Krystal Biotech Inc (KRYS)
Cowen & Co. analyst Ritu Baral maintained a Buy rating on Krystal Biotech Inc yesterday. The company’s shares closed last Monday at $41.80.
According to TipRanks.com, Baral is a 5-star analyst with an average return of 21.5% and a 46.3% success rate. Baral covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals Inc, Madrigal Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Krystal Biotech Inc with a $68.50 average price target, which is a 63.3% upside from current levels. In a report issued on August 5, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Prevail Therapeutics Inc (PRVL)
In a report released yesterday, Yaron Werber from Cowen & Co. maintained a Buy rating on Prevail Therapeutics Inc. The company’s shares closed last Monday at $10.36.
According to TipRanks.com, Werber is a 4-star analyst with an average return of 10.3% and a 61.5% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Stoke Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Prevail Therapeutics Inc with a $20 average price target.
Intec Pharma Ltd (NTEC)
In a report issued on August 13, Jason McCarthy from Maxim Group maintained a Hold rating on Intec Pharma Ltd. The company’s shares closed last Monday at $0.51, close to its 52-week low of $0.41.
McCarthy observed:
“On 8/9, Intec reported 2Q19 with a net loss of ($10M) and ended the period with $21.6M in cash on the balance sheet. Operating expenses are expected to be reduced with the P3 trial in Parkinson’s disease now over. The company is evaluating the data for AP-CD/LD to determine what the next steps may be. While the P3 trial outcome was a disappointment, it’s worth noting that the delivery technology that is the foundation of Intec as a company, did deliver the levodopa as it was supposed to. In addition, there are subgroup data that suggest trial design could be different and potentially have success, in our view. Nonetheless, it’s too early to tell and as we await more clarity, we remain Hold rated.”
According to TipRanks.com, McCarthy has currently no stars on a ranking scale of 0-5 stars, with an average return of -24.1% and a 21.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Inc., Hancock Jaffe Laboratories Inc, and Aridis Pharmaceuticals Inc.
The word on The Street in general, suggests a Hold analyst consensus rating for Intec Pharma Ltd with a $0.50 average price target, which is a -2.0% downside from current levels. In a report issued on August 7, H.C. Wainwright also downgraded the stock to Hold.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
